Hack, C. C., Haeberle, L., Brucker, S. Y., Janni, W., Volz, B., Loehberg, C. R., Hartkopf, A. D., Walter, C-B, Baake, G., Fridman, A., Malter, W., Wuerstlein, R., Harbeck, N., Hoffmann, O., Kuemmel, S., Martin, B., Thomssen, C., Graf, H., Wolf, C., Lux, M. P., Bayer, C. M., Rauh, C., Almstedt, K., Gass, P., Heindl, F., Brodkorb, T., Willer, L., Lindner, C., Kolberg, H-C, Krabisch, P., Weigel, M., Steinfeld-Birg, D., Kohls, A., Brucker, C., Schulz, V, Fischer, G., Pelzer, V, Rack, B., Beckmann, M. W., Fehm, T., Rody, A., Maass, N., Hein, A., Fasching, P. A. and Nabieva, N. (2020). Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients. Breast, 50. S. 11 - 19. EDINBURGH: CHURCHILL LIVINGSTONE. ISSN 1532-3080

Full text not available from this repository.

Abstract

Background: Patients with breast cancer (BC) show strong interest in complementary and alternative medicine (CAM), particularly for adverse effects of adjuvant endocrine treatment - e.g., with letrozole. Letrozole often induces myalgia/limb pain and arthralgia, with potential noncompliance and treatment termination. This analysis investigated whether CAM before aromatase inhibitor (AI) therapy is associated with pain development and the intensity of AI-induced musculoskeletal syndrome (AIMSS) during the first year of treatment. Patients and methods: The multicenter phase IV PreFace study evaluated letrozole therapy in post-menopausal, hormone receptor-positive patients with early BC. Patients were asked about CAM use before, 6 months after, and 12 months after treatment started. They recorded pain every month for 1 year in a diary including questions about pain and numeric pain rating scales. Data were analyzed for patients who provided pain information for all time points. Results: Of 1396 patients included, 901 (64.5%) had used CAM before AI treatment. Throughout the observation period, patients with CAM before AI treatment had higher pain values, for both myalgia/limb pain and arthralgia, than non-users. Pain increased significantly in both groups over time, with the largest increase during the first 6 months. No significant difference of pain increase was noted regarding CAM use. Conclusions: CAM use does not prevent or improve the development of AIMSS. Pain intensity was generally greater in the CAM group. Therefore, because of the risk of non-compliance and treatment discontinuation due to the development of higher pain levels, special attention must be paid to patient education and aftercare in these patients. (C) 2020 The Author(s). Published by Elsevier Ltd.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Hack, C. C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Haeberle, L.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Brucker, S. Y.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Janni, W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Volz, B.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Loehberg, C. R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hartkopf, A. D.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Walter, C-BUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Baake, G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fridman, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Malter, W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wuerstlein, R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Harbeck, N.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hoffmann, O.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kuemmel, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Martin, B.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Thomssen, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Graf, H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wolf, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lux, M. P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bayer, C. M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rauh, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Almstedt, K.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gass, P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Heindl, F.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Brodkorb, T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Willer, L.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lindner, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kolberg, H-CUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Krabisch, P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Weigel, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Steinfeld-Birg, D.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kohls, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Brucker, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schulz, VUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fischer, G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pelzer, VUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rack, B.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Beckmann, M. W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fehm, T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rody, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Maass, N.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hein, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fasching, P. A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Nabieva, N.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-339674
DOI: 10.1016/j.breast.2019.12.017
Journal or Publication Title: Breast
Volume: 50
Page Range: S. 11 - 19
Date: 2020
Publisher: CHURCHILL LIVINGSTONE
Place of Publication: EDINBURGH
ISSN: 1532-3080
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
POSTMENOPAUSAL WOMEN; INDUCED ARTHRALGIA; ENDOCRINE THERAPY; CONTROLLED TRIAL; FREE SURVIVAL; SYMPTOMS; TAMOXIFEN; ACUPUNCTURE; PERSONALITY; ANASTROZOLEMultiple languages
Oncology; Obstetrics & GynecologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/33967

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item